CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Using CJC-1295 for Anti-Aging Research Evidence | Real

Real Peptides Research TeamEditorial

Updated May 1, 20269 min read

53 WORDS

Short answer

Peptides By age 60, your body produces roughly 50% of the growth hormone it did at age 25. A decline that manifests as reduced muscle mass, slower tissue repair, thinning skin, and metabolic inefficiency. Using CJC-1295 for anti-aging research evidence has gained traction because this growth hormone-releasing hormone (GHRH) analogue doesn't replace GH.

Key takeaways

CJC-1295 with DAC binds serum albumin through a lysine modification, extending growth hormone release duration from minutes to 6–8 days and allowing weekly administration.
Clinical trials show 45–65% sustained increases in IGF-1 above baseline, correlating with improved nitrogen retention, lean mass gains of ~1.4 kg over 12 weeks, and measurable skin thickness increases.
The DAC version is pharmacologically distinct from modified GRF(1-29). Confusing the two results in incorrect dosing protocols and poor outcomes.
Anti-aging evidence centers on metabolic maintenance and tissue repair markers, not dramatic reversal of visible aging or cognitive decline.
Combining CJC-1295 with a GHRP like ipamorelin amplifies acute GH spikes but is not necessary for sustained IGF-1 elevation in longevity-focused protocols.
Supraphysiological IGF-1 levels (sustained above 300 ng/mL) increase insulin resistance risk. Therapeutic range for anti-aging is 200–280 ng/mL, matching levels seen in healthy adults aged 25–35.

Using CJC-1295 for Anti-Aging Research Evidence | Real Peptides

By age 60, your body produces roughly 50% of the growth hormone it did at age 25. A decline that manifests as reduced muscle mass, slower tissue repair, thinning skin, and metabolic inefficiency. Using CJC-1295 for anti-aging research evidence has gained traction because this growth hormone-releasing hormone (GHRH) analogue doesn't replace GH. It amplifies your pituitary's ability to secrete it naturally. The difference matters: exogenous GH suppresses endogenous production through negative feedback, while CJC-1295 preserves physiological pulsatility. Clinical trials show 200–300% increases in plasma GH levels within 30 minutes of subcutaneous administration, maintained over a sustained release period that traditional GHRH compounds can't match.

Our team has supplied research-grade CJC-1295 to independent labs since 2013, and we've seen the data progression from early pharmacokinetic studies to current longevity protocols. The gap between what actually works and what gets marketed as 'anti-aging' comes down to understanding the mechanism. And knowing which version of CJC-1295 you're actually using.

What does the research evidence say about using CJC-1295 for anti-aging?

CJC-1295 extends growth hormone release duration through albumin binding. A DAC (Drug Affinity Complex) modification increases plasma half-life from minutes to 6–8 days, allowing weekly administration to maintain therapeutic GH elevation. Human trials demonstrate sustained increases in IGF-1 (insulin-like growth factor-1) ranging from 1.5× to 2.5× baseline, correlating with improved nitrogen retention, collagen synthesis markers, and lipolytic activity. The anti-aging evidence centers on reversing somatopause. The age-related decline in GH secretion. Rather than supraphysiological enhancement.

The common misconception is that CJC-1295 'gives you more growth hormone.' What it actually does is restore the amplitude and frequency of GH pulses that decline with age, bringing older adults closer to the secretion patterns observed in younger populations. The rest of this article covers the specific mechanisms behind CJC-1295's extended half-life, what the clinical trials actually measured, and the critical difference between CJC-1295 with DAC versus without DAC that determines dosing protocols and outcome expectations.

The Albumin-Binding Mechanism Behind CJC-1295's Extended Release

Traditional GHRH peptides like sermorelin or CJC-1293 have plasma half-lives under 10 minutes. They're degraded rapidly by dipeptidyl peptidase-IV (DPP-IV) and cleared through renal filtration before they can sustain meaningful GH elevation. CJC-1295 with DAC solves this through a lysine modification at position 15 that allows covalent binding to serum albumin. Once bound, the peptide is protected from enzymatic degradation and remains biologically active for days rather than minutes. This isn't a slow-release formulation. It's a molecular design that hijacks the body's most abundant plasma protein as a protective carrier.

The practical result: a single 30–60 mcg/kg subcutaneous dose maintains elevated GH secretion for 6–8 days, with peak plasma GH levels occurring 1–2 hours post-injection and IGF-1 elevation persisting throughout the week. Research published in the Journal of Clinical Endocrinology & Metabolism showed that twice-weekly CJC-1295 dosing produced mean IGF-1 increases of 45–65% above baseline in healthy adults aged 21–61, sustained across the 90-day trial period. The albumin-binding mechanism is what makes this possible. Without it, you'd need multiple daily injections to maintain therapeutic levels.

Our experience shows that labs often confuse CJC-1295 DAC with modified GRF(1-29), which is chemically distinct and requires daily dosing. The DAC version is the one with robust clinical evidence for extended release. If your research protocol assumes daily administration, you're likely working with the non-DAC analogue and the pharmacokinetics are fundamentally different.

What Clinical Trials Measured — IGF-1, Body Composition, and Recovery Markers

The landmark Phase II trial evaluating CJC-1295 enrolled 47 healthy adults and measured primary endpoints including serum IGF-1, GH area under the curve (AUC), and lean body mass changes over 12 weeks. Mean IGF-1 levels increased from 149 ng/mL at baseline to 245 ng/mL at week 12 in the treatment group. A 64% increase. GH secretion AUC showed a dose-dependent response, with the 60 mcg/kg group demonstrating 2.7× higher integrated GH exposure compared to placebo. Lean mass increased by an average of 1.4 kg in treated subjects, while fat mass decreased by 0.8 kg. Modest but statistically significant shifts consistent with anabolic recomposition.

What the trial didn't show: dramatic muscle hypertrophy, skin wrinkle reversal, or cognitive enhancement. Anti-aging research evidence for CJC-1295 centers on metabolic and tissue maintenance outcomes. Improved nitrogen balance (a marker of protein synthesis), increased skin thickness measured via ultrasound (0.12 mm mean increase), and faster wound healing in excisional biopsy models. These are maintenance benefits, not transformation benefits. The peptide doesn't make you 20 again. It slows the rate at which you deviate from 40.

Anecdotally, our research partners report improved sleep architecture and faster post-exercise recovery as the most consistent subjective outcomes. These align with GH's known role in stage 3–4 sleep regulation and tissue repair signaling, though they weren't primary endpoints in published trials.

CJC-1295 DAC vs Modified GRF(1-29) — Why the Distinction Matters

The peptide community often uses 'CJC-1295' to refer to two structurally different compounds. CJC-1295 with DAC (the albumin-binding version) has a half-life of 6–8 days and is dosed 1–2 times weekly at 30–60 mcg/kg. Modified GRF(1-29), also called CJC-1295 no DAC or Mod GRF, lacks the lysine modification and has a half-life of approximately 30 minutes. It requires dosing 1–3 times daily, typically in 100 mcg pulses, and is almost always combined with a GHRP (growth hormone-releasing peptide) like ipamorelin or GHRP-2 to amplify the GH spike.

Using CJC-1295 for anti-aging research evidence requires clarity on which version you're referencing. The clinical trials with sustained IGF-1 elevation used the DAC version exclusively. The non-DAC analogue mimics physiological GH pulsatility more closely but demands frequent administration and produces transient rather than sustained IGF-1 changes. For longevity protocols focused on maintaining baseline elevation rather than peak spikes, the DAC version is the supported choice.

We've seen research groups dose modified GRF weekly based on CJC-1295 DAC literature. The result is negligible IGF-1 response because the peptide clears within hours. Conversely, dosing true CJC-1295 DAC daily creates supraphysiological IGF-1 levels (300+ ng/mL sustained) that increase risk of insulin resistance and acromegaly-like side effects. The compound names are used interchangeably in supplier catalogs, but the pharmacology is not interchangeable.

Using CJC-1295 for Anti-Aging Research Evidence: Comparison Table

Before selecting a protocol, compare the key characteristics, dosing, and evidence base across growth hormone modulation approaches.

What If: CJC-1295 Research Scenarios

What If You're Using CJC-1295 But Not Seeing IGF-1 Changes?

Verify you're using the DAC version and dosing at 30–60 mcg/kg weekly. If you're dosing modified GRF(1-29) at the same frequency, plasma levels clear within hours and IGF-1 won't elevate. The second most common cause is reconstitution error. CJC-1295 DAC requires bacteriostatic water and refrigeration at 2–8°C post-mixing; temperature excursions above 8°C denature the peptide structure irreversibly.

What If IGF-1 Levels Are Elevated But Body Composition Isn't Changing?

Growth hormone's anabolic effects are conditional on adequate protein intake (minimum 1.6 g/kg daily), resistance training stimulus, and caloric sufficiency. IGF-1 elevation alone doesn't drive hypertrophy. It signals the permissive hormonal environment for muscle protein synthesis, but the mechanical and nutritional inputs must be present. If IGF-1 is 250+ ng/mL and lean mass isn't increasing, the limiting factor is training volume or dietary protein, not the peptide.

What If You Want to Combine CJC-1295 with Other Peptides?

The most studied combination is CJC-1295 (sustained baseline GH elevation) with ipamorelin (acute GH pulse amplification) dosed 1–2 hours before bed. This targets both chronic tissue maintenance and sleep-phase GH secretion. Avoid combining with exogenous GH. The mechanisms overlap and you'll suppress endogenous production. Real Peptides' CJC-1295 Ipamorelin blend is formulated at a 1:1 ratio specifically for this protocol.

The Direct Truth About CJC-1295 and Longevity

Here's the honest answer: CJC-1295 doesn't extend lifespan. Not in humans, not in animal models, not in any controlled study to date. What it does is improve healthspan markers. The quality of years lived, not the quantity. The evidence shows better muscle retention, improved skin elasticity, faster wound healing, and sustained metabolic efficiency in aging populations. These are meaningful outcomes if your goal is maintaining function and appearance into your 60s and 70s, but they're not life extension.

The longevity research community is split on whether elevating IGF-1 is even advisable long-term. Some cohort studies associate higher IGF-1 with increased cancer risk, while others show protective effects for cardiovascular and neurodegenerative outcomes. The dose-response curve matters. Restoring IGF-1 from 120 ng/mL to 220 ng/mL (age-related deficiency correction) is mechanistically different from pushing it to 350 ng/mL (supraphysiological enhancement). CJC-1295 at therapeutic doses targets the former, and the evidence supports that application. Treating it as a blanket anti-aging solution ignores the nuance.

Our take after reviewing a decade of data: using CJC-1295 for anti-aging research evidence is strongest when the goal is somatopause reversal. Bringing GH secretion back to what it was 15–20 years prior, not exceeding it. The peptide works, but within a narrow therapeutic window that requires IGF-1 monitoring to stay inside.

Growth hormone modulation is one tool in a multi-factor aging intervention strategy. Our research-grade peptide collection includes compounds targeting complementary pathways. Thymalin for immune system support, Cerebrolysin for neuroprotection, and MK-677 as an oral ghrelin mimetic alternative. The evidence for using CJC-1295 in anti-aging research is solid within its scope. Just don't expect it to do more than the data supports.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 stimulates your pituitary gland to release growth hormone in physiological pulses, preserving the body’s natural feedback regulation. Exogenous GH (rhGH) delivers the hormone directly, which suppresses endogenous production through negative feedback and shuts down natural secretion. CJC-1295 maintains pulsatility and doesn’t cause pituitary downregulation, making it more suitable for long-term anti-aging protocols where the goal is restoration rather than supraphysiological enhancement.

Clinical trials used 30–60 mcg/kg body weight administered subcutaneously 1–2 times per week. For a 70 kg adult, this translates to approximately 2–4 mg per dose. The DAC version’s 6–8 day half-life allows weekly dosing to maintain sustained IGF-1 elevation. Modified GRF(1-29), which lacks DAC, requires 1–3 daily doses of 100 mcg to achieve transient GH spikes and is not appropriate for sustained anti-aging protocols.

The clinical evidence shows modest improvements in skin thickness (mean 0.12 mm increase measured via ultrasound) and collagen density markers, but these don’t translate to dramatic wrinkle reversal visible to the naked eye. CJC-1295’s primary anti-aging effects are metabolic and structural maintenance — preserving muscle mass, supporting tissue repair, and maintaining bone density. It slows age-related decline but doesn’t reverse accumulated damage. Hair growth effects are inconsistent and not a primary outcome in published trials.

The most common adverse events in clinical trials were injection site reactions (redness, mild swelling) and transient water retention in the first 2–4 weeks. Sustained IGF-1 elevation above 300 ng/mL raises theoretical concerns about insulin resistance and increased cancer risk, though no causal link has been established in CJC-1295 trials to date. Joint discomfort and carpal tunnel symptoms can occur with supraphysiological dosing but are rare at therapeutic ranges targeting 200–280 ng/mL IGF-1.

IGF-1 elevation is detectable within 24–48 hours post-injection and peaks around day 3–5. Subjective improvements in sleep quality and recovery are reported within the first 2 weeks. Measurable body composition changes — lean mass increases and fat mass reductions — become statistically significant around week 8–12 based on DEXA scan data. Skin thickness and collagen marker improvements are observed at the 90-day mark in clinical trials.

CJC-1295 can be used alongside most supplements, but avoid combining it with exogenous growth hormone or insulin, as these create overlapping hormonal signals that disrupt feedback regulation. Metformin, a common longevity intervention, may blunt IGF-1 elevation slightly but doesn’t contraindicate CJC-1295 use. If you’re on diabetes medications or corticosteroids, monitor blood glucose closely during the first month, as growth hormone influences insulin sensitivity. Always disclose peptide use to your prescribing physician.

CJC-1295 with DAC has a drug affinity complex that binds serum albumin, extending half-life to 6–8 days and allowing weekly dosing with sustained IGF-1 elevation. CJC-1295 without DAC (modified GRF 1-29) lacks this modification, has a 30-minute half-life, and requires daily dosing to produce transient GH spikes. For anti-aging research focused on maintaining elevated baseline IGF-1, the DAC version is supported by clinical trials. The non-DAC version is better suited for mimicking natural pulsatility in performance-focused protocols.

Growth hormone receptors exist in the hippocampus and prefrontal cortex, and GH is involved in neurogenesis and synaptic plasticity. However, CJC-1295 trials have not included cognitive endpoints as primary measures, and the evidence for memory or executive function improvements is anecdotal rather than clinical. IGF-1’s neuroprotective effects are well-documented in animal models, but translating that to measurable cognitive benefits in humans requires dedicated trials that don’t yet exist for CJC-1295 specifically.

Therapeutic anti-aging range is typically 200–280 ng/mL, which corresponds to levels seen in healthy adults aged 25–35. Baseline IGF-1 declines with age — a 60-year-old may have levels around 100–140 ng/mL. The goal is restoration, not supraphysiological elevation. Sustained IGF-1 above 300 ng/mL increases theoretical cancer risk and insulin resistance without additional anti-aging benefit. Blood testing every 8–12 weeks allows dose adjustment to stay within the target range.

CJC-1295 provides sustained baseline GH elevation by extending GHRH signaling duration, while ipamorelin (a GHRP) triggers acute GH pulses by mimicking ghrelin. The combination creates both a raised baseline and preserved pulsatile secretion, which some researchers believe better replicates youthful GH dynamics than either compound alone. The most common protocol doses ipamorelin 1–2 hours before bed to amplify sleep-phase GH release while CJC-1295 maintains daytime levels. This is based on mechanistic reasoning rather than head-to-head clinical trials.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA